[Treatment of chronic portal-systemic encephalopathy with lactulose (synthetic disaccharide: one molecule of galactose and one of fructose)].
Explore the source record for details and available documents.
Adult↗
Biomedical subjects
L Cova
Publications and source records attributed to L Cova.
Percutaneous ethanol injection of autonomously functioning thyroid nodule.
Percutaneous ethanol injection (PEI) is proposed for treatment of autonomously functioning thyroid nodule, especially for small-mid-sized solitary nodules, for patients refusing the other methods or not proving responsive to radioiodine, or for patients with non toxic nodule. The injection is performed under color Doppler sonography guidance, evaluating the most vascularized areas of the tumor where to primarily inject ethanol solution with 21-22 gauge needles. Serum TSH, FT4, FT3 and TG levels are measured before each treatment session and 3,6,12,24 and 36 months after the end of therapy. Complete remission was achieved by different authors in 86% of cases and the efficacy of response was shown to be inversely proportional to the nodule volume. When TSH remains undetectable, a second cycle of PEI can be performed. If there is complete lack of blood flow signals on color or power Doppler with persisting thyroid hyperfunction, sonographic contrast media can be administered i.v. to assess residual areas of intranodal hypervascularity. In patients with unsuppressed TSH levels before treatment, hormonal changes cannot be used as marker response. Disappearance of nodular hypervascularity at color Doppler sonography and complete normalization of the scintigraphic pattern is usually observed in all cases. PEI is generally well tolerated; no recurrences of the disease and no cases of hypothyroidism have been reported.
Ethanol↗
[Changes in IGFBP-3 in relation to administration of rGH to deficient children].
Serum IGFBP3 levels were tested in 7 GHD children before the rGH therapy, at the end of the same therapy and 1, 2, 4, and 8 weeks later. The IGFBP3 concentration returned to the pre-therapy levels only 6 weeks after the end of the therapy.
Carrier Proteins↗
[IGFBP3 in the assessment of growth hormone defects].
Evaluation of growth hormone dependent IGFBP3, stable in time and with no circadian variations is a useful parameter for diagnosing growth hormone deficit. The IGFBP3 was evaluated using sera, collected and kept at -20 degrees C, from subjects classified according to auxologic characters and response sup. or inf. to 8 ng/ml GH after two stimulation tests and median nocturnal GH sup. or inf. to 3 ng/ml. Two groups were studied: 1) Small stature GHD (growth hormone deficiency): 14 cases; 2) Constitutional small stature (RCC,BSF): 12 cases. A third group composed of 8 normal height, weight and disease-free children formed the control group. The IGFBP3 values were below the 5th percentile in 86% of GHD cases, between the 5th and 95th percentile in 66.6% of constitutionally short stature children and in all normal controls was about the 50th percentile. The IGFBP3 also shows a statistically significant correlation between median nocturnal GH, both in deficient and constitutionally short stature groups (p < 0.01).
Adolescent↗